154 related articles for article (PubMed ID: 18504399)
41. Different effects of cyclic AMP and butyrate on eosinophilic differentiation, apoptosis and bcl-2 expression of a human eosinophilic leukemia cell line, EoL-1.
Tai G; Eun-Young J; Yuji H; Masahiko K; Toshio H; Kenji K; Kenshi F; Mitsufumi M
Hematol Oncol; 1996 Dec; 14(4):181-92. PubMed ID: 9267464
[TBL] [Abstract][Full Text] [Related]
42. [Identification of FIP1L1-PDGFRA fusion, and expression of signal transducer and activator of transcription 5 in hypereosinophilic syndrome].
Zhang GS; Li B; Pei MF; Dai CW; Zheng WL; Shen JK
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1541-4. PubMed ID: 15500716
[TBL] [Abstract][Full Text] [Related]
43. Cardiac Imaging in FIP1L1-PDGFRA.
Jaworski C; Looi JL; Martin J; Bergin P; Hare J; Kaye D; Wei A; Taylor AJ
J Am Coll Cardiol; 2013 Oct; 62(14):1304. PubMed ID: 23933546
[No Abstract] [Full Text] [Related]
44. Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions.
Score J; Walz C; Jovanovic JV; Jones AV; Waghorn K; Hidalgo-Curtis C; Lin F; Grimwade D; Grand F; Reiter A; Cross NC
Leukemia; 2009 Feb; 23(2):332-9. PubMed ID: 18987650
[TBL] [Abstract][Full Text] [Related]
45. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
[TBL] [Abstract][Full Text] [Related]
46. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
[TBL] [Abstract][Full Text] [Related]
47. Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity.
Řezníčková E; Gucký T; Kováčová V; Ajani H; Jorda R; Kryštof V
Eur J Med Chem; 2019 Nov; 182():111663. PubMed ID: 31514019
[TBL] [Abstract][Full Text] [Related]
48. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
[TBL] [Abstract][Full Text] [Related]
49. Regulation of adipocyte differentiation by histone deacetylase inhibitors.
Kim SN; Choi HY; Kim YK
Arch Pharm Res; 2009 Apr; 32(4):535-41. PubMed ID: 19407971
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.
Karasawa Y; Okisaka S
Jpn J Ophthalmol; 2004; 48(6):542-51. PubMed ID: 15592778
[TBL] [Abstract][Full Text] [Related]
51. FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Gilliland G; Cools J; Stover EH; Wlodarska I; Marynen P
Hematol J; 2004; 5 Suppl 3():S133-7. PubMed ID: 15190295
[No Abstract] [Full Text] [Related]
52. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.
Toffalini F; Kallin A; Vandenberghe P; Pierre P; Michaux L; Cools J; Demoulin JB
Haematologica; 2009 Aug; 94(8):1085-93. PubMed ID: 19644140
[TBL] [Abstract][Full Text] [Related]
53. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Florian S; Esterbauer H; Binder T; Müllauer L; Haas OA; Sperr WR; Sillaber C; Valent P
Leuk Res; 2006 Sep; 30(9):1201-5. PubMed ID: 16406018
[TBL] [Abstract][Full Text] [Related]
54. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
55. Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis.
Chen J; Du C; Kang J; Wang J
Chem Biol Interact; 2008 Jan; 171(1):26-36. PubMed ID: 17961528
[TBL] [Abstract][Full Text] [Related]
56. Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Park H; Im JY; Kim J; Choi WS; Kim HS
Int J Mol Med; 2008 Mar; 21(3):325-33. PubMed ID: 18288380
[TBL] [Abstract][Full Text] [Related]
57. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes.
Rada-Iglesias A; Enroth S; Ameur A; Koch CM; Clelland GK; Respuela-Alonso P; Wilcox S; Dovey OM; Ellis PD; Langford CF; Dunham I; Komorowski J; Wadelius C
Genome Res; 2007 Jun; 17(6):708-19. PubMed ID: 17567991
[TBL] [Abstract][Full Text] [Related]
58. [Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Borbényi Z
Orv Hetil; 2005 May; 146(18 Suppl 1):911-6. PubMed ID: 15921304
[TBL] [Abstract][Full Text] [Related]
59. Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: a surrogate marker of response?
Pitini V; Arrigo C; Altavilla G; Naro C; Righi M
Leuk Res; 2007 May; 31(5):725-6. PubMed ID: 16978696
[No Abstract] [Full Text] [Related]
60. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ueda T; Takai N; Nishida M; Nasu K; Narahara H
Int J Mol Med; 2007 Feb; 19(2):301-8. PubMed ID: 17203205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
